Trial Profile
Metabolic alteration with perhexiline therapy in patients with hypertrophic cardiomyopathy (METAL-HCM Study)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jun 2016
Price :
$35
*
At a glance
- Drugs Perhexiline (Primary)
- Indications Cardiomyopathies
- Focus Therapeutic Use
- Acronyms METAL-HCM
- 03 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Oct 2009 New source identified and integrated (United Kingdom Clinical Research Network, 4707).
- 16 Oct 2009 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.